OncoSTRAT&GO test aims at guiding oncologists in their treatment decision making thanks to a very innovative and unique dual solid/liquid molecular characterization of the tumor. Sophisticated tumor interrogation technologies (NGS, IHC, pyrosequencing,...) combined with an extensive clinical literature assessment allow us to provide you with the most relevant evidence on biomarkers and their drugs correlation.

This innovative coupled analysis allows you to:

- **Decipher** the heterogeneity of the tumour and its related metastases
- **Overcome** rebiopsy issues
- **Open doors** for personalized monitoring of the disease

Our multiplex platform helps guide therapy decisions when there is little to no medical treatment consensus or guideline and offers you to:

- **Navigate** among therapies with potential clinical benefit
- **Identify** therapies that may not have been considered previously
- **Detect** drugs with potential lack of clinical benefit (thus avoiding unnecessary toxicities and costs)
- **Match** patients to clinical trial opportunities

**MATERIAL**

1 block or 25 slides (5μm on super Frost+) / 1 blood sample (2 Streck tubes of 10 ml each)

**DUAL TUMOR MOLECULAR PROFILING** (SOLID AND LIQUID VIEW OF THE DISEASE)

**SOLID BIOPSY**

- Next-generation sequencing
  - More than 150 genes, hotspots and CDS
  - More than 350 gene fusions (translocations analyses)
  - Depth of coverage at a median of 1000x
  - Selection of up to 15 variants for potential further OncotRACE analyses

**CANCER TYPE SPECIFIC PACKAGE**

- IHCs for targeted therapies
- IHCs for chemotherapies
- Other (unusual splicing, methylation)
- **NEW!** Immunogram (MSI + TMB)

**LIQUID BIOPSY**

- Next-generation sequencing
  - **NEW!** 40 genes associated with resistance or sensitivity to targeted therapies (SNV, Indel and CNV) (previous panel: 28)

**INTEGRATED THERANOSTIC REPORT**

- Molecular characterization of the tumor
- Liquid biopsy view
- Treatment options for targeted therapies, chemotherapies and immunotherapies
- Clinical trials availability

OncoSTRAT&GO is IVD CE-marked and processed in an ISO 15189 accredited laboratory.
WHY IS ONCOSTRAT&GO UNIQUE?

OncoSTRAT&GO is the only comprehensive and the most disruptive solution on the market for metastatic cancer. It combines an analysis of the solid tumor, an extensive OncoDEEP, and an analysis of the cell-free circulating DNA from a blood sample delivering a complete picture of the disease.

Data generated from both the next-generation sequencing and molecular pathology analyses are integrated and interpreted in a biological review. Our reports are sent to oncologists worldwide via our interactive web platform OncoSHARE, an innovative and proprietary application specifically created to centralize data, facilitate their access and guarantee their confidentiality.

HOW LONG DOES IT TAKE TO GET THE RESULTS?

Once OncoDNA has received and QC checked all samples, both solid and liquid, and the required clinical information, we are committed to sending the report within 10 working days.

WHO IS THIS TEST FOR?

OncoSTRAT&GO is designed to be used in adults with metastatic or non-resectable solid cancers as:

- Highly aggressive or rare cancers for which treatment protocols are limited
- Cancers treated with targeted therapies where hotspots of resistance must be found to benefit for 2nd and 3rd generation of targeted therapy treatments
- And/or when treatment and attentive response monitoring are highly desirable